Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena, Like Rivals, Greets Mixed Phase III Obesity Results With Brave Face

Executive Summary

Arena's release this week of surprisingly disappointing results for its obesity drug lorcaserin raises more questions about what "efficacy" means in the highly competitive space, and about the flexibility of FDA guidance for weight-management products
Advertisement

Related Content

Amylin And Takeda Team Up In Obesity
Amylin And Takeda Team Up In Obesity
Obesity Déjà Vu: Arena Airs More Mixed Phase III Data
Orexigen obesity drug Contrave adds more Phase III success
Market Snapshot: Obesity Space Is ‘Not For The Faint of Heart’
FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately
Arena Defends Obesity Drug After Phase III BLOOM Wilts
Orexigen Starts Partnership Talks On Obesity Drug Contrave
Vivus’ Qnexa Combo For Obesity Needs FDA ‘Persuasion’ To Take First-Line In Diabetes
Obesity Guidance Should Be More Lenient On Indications, Firms Tell FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS050894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel